Incidence of End‐Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry
Open Access
- 3 August 2015
- journal article
- systemic lupus-erythematosus
- Published by Wiley in Arthritis Care & Research
- Vol. 68 (3) , 357-365
Abstract
Objective: To estimate and identify factors associated with the incidence of all‐cause end‐stage renal disease (ESRD) among newly diagnosed systemic lupus erythematosus (SLE) patients.Methods: Data from a national registry of treated ESRD were linked to data from a lupus registry of SLE patients who were newly diagnosed and living in Atlanta, Georgia, 2002–2004 (median followup 7.8 years). Cumulative incidence and incidence rates (ESRD treatment initiations per 1,000 patient‐years) were calculated, and age‐ and race‐adjusted Poisson models were used to calculate incidence rate ratios (IRRs).Results: Among 344 newly diagnosed SLE patients, 29 initiated ESRD treatment over 2,603.8 years of followup. Incidence rates were 13.8 (95% confidence interval [95% CI] 9.4–20.3) among black patients and 3.3 (95% CI 0.8–13.0) among white patients, per 1,000 patient‐years; corresponding 5‐year cumulative incidence was 6.4% and 2.5% among black and white patients, respectively. Lupus nephritis documented prior to 2005, which occurred in 80% of those who progressed to ESRD, was the strongest risk factor for incident ESRD (IRR 6.7 [95% CI 2.7–16.8]; incidence rate 27.6 per 1,000 patient‐years). Results suggested that patients who were black versus white (IRR 3.9 [95% CI 0.9–16.4]) or <18 years old (versus ≥30 years old) at diagnosis (IRR 2.1 [95% CI 0.9–5.3]) may be more likely to progress to ESRD, but incidence did not differ by sex or other characteristics.Conclusion: The incidence of all‐cause ESRD among patients with a recent diagnosis of SLE is high in Georgia. Interventions to decrease ESRD incidence among newly diagnosed SLE patients should target young and black patients, as well as patients with lupus nephritis.Keywords
Funding Information
- Laney Graduate School at Emory University
- Lupus Foundation of America
- NIH (R01-AR-065493, U01-DP-005119)
- National Center for Advancing Translational Sciences, a division of the NIH (UL1-TR-000454, KL2-TR-000455)
- National Institute on Minority Health and Health Disparities (1R24MD008077-01, 1R24MD008077-01)
This publication has 45 references indexed in Scilit:
- Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohortAnnals of the Rheumatic Diseases, 2013
- American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisArthritis Care & Research, 2012
- End-stage renal disease due to lupus nephritis among children in the US, 1995-2006Arthritis & Rheumatism, 2011
- Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006Arthritis & Rheumatism, 2011
- Increased risk of death in pediatric and adult patients with ESRD secondary to lupusPediatric Nephrology, 2010
- Access to Care and the Incidence of Endstage Renal Disease Due to Systemic Lupus ErythematosusThe Journal of Rheumatology, 2010
- Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohortArthritis Care & Research, 2009
- Changes in the Incidence of Endstage Renal Disease Due to Lupus Nephritis in the United States, 1996–2004The Journal of Rheumatology, 2009
- Prevalence of Systemic Lupus Erythematosus and Associated Comorbidities in Puerto RicoJCR: Journal of Clinical Rheumatology, 2007
- Time to Renal Disease and End-Stage Renal Disease in PROFILE: A Multiethnic Lupus CohortPLOS Medicine, 2006